Keywords
Last Name
Institution

Michael B. Lilly

TitleEndowed Chair, Oliver S. and Jennie R. Donaldson Charitable Trust Endowed Chair
InstitutionMedical University of South Carolina
DepartmentHematology/Oncology
AddressP.O. Box MSC 635
355A
86 Jonathan Lucas St.
Phone843-792-4271
vCardDownload vCard

    Collapse Overview 
    Collapse keywords
    Cancer, Cancer/Breast, Cancer/Gastrointestinal, Cancer/Genitourinary, Cancer/Lung, Men-s Health, Cancer/Lymphoma, Cancer/Other, Drug Studies, Prostate, Healthy Volunteer Studies

    Collapse ORNG Applications 
    Collapse studies/trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer. 2019 May 01; 125(9):1459-1469. PMID: 30620391.
      View in: PubMed
    2. Walter KR, Ford ME, Gregoski MJ, Kramer RM, Knight KD, Spruill L, Nogueira LM, Krisanits BA, Phan V, La Rue AC, Lilly MB, Ambs S, Chan K, Turner TF, Varner H, Singh S, Uribarri J, Garrett-Mayer E, Armeson KE, Hilton EJ, Clair MJ, Taylor MH, Abbott AM, Findlay VJ, Peterson LL, Magwood G, Turner DP. Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention. Breast Cancer Res Treat. 2019 Feb; 173(3):559-571. PMID: 30368741.
      View in: PubMed
    3. Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN. Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol. 2018 Oct 19; JCO1800328. PMID: 30339520.
      View in: PubMed
    4. Goicochea NL, Garnovskaya M, Blanton MG, Chan G, Weisbart R, Lilly MB. Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy. Protein Eng Des Sel. 2017 12 01; 30(12):785-793. PMID: 29228299.
      View in: PubMed
    5. Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest. 2017 06 01; 127(6):2438. PMID: 28569734.
      View in: PubMed
    6. Rice LJ, Jefferson M, Briggs V, Delmoor E, Johnson JC, Gattoni-Celli S, Savage SJ, Lilly M, Prasad SM, Kittles R, Halbert CH. Discordance in perceived risk and epidemiological outcomes of prostate cancer among African American men. Prev Med Rep. 2017 Sep; 7:1-6. PMID: 28507891.
      View in: PubMed
    7. Liu G, Zhang J, Frey L, Gang X, Wu K, Liu Q, Lilly M, Wu J. Prostate-specific IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose tissue. J Hematol Oncol. 2017 01 11; 10(1):14. PMID: 28077171.
      View in: PubMed
    8. Habiel DM, Krepostman N, Lilly M, Cavassani K, Coelho AL, Shibata T, Elenitoba-Johnson K, Hogaboam CM. Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma. Oncotarget. 2016 Dec 13; 7(50):83514-83529. PMID: 27835864.
      View in: PubMed
    9. Li X, Yokoyama NN, Zhang S, Ding L, Liu HM, Lilly MB, Mercola D, Zi X. Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model. Oncotarget. 2015 Dec 08; 6(39):41809-24. PMID: 26497688.
      View in: PubMed
    10. Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, Drake RR, Kraveka JM, Smith CD, Voelkel-Johnson C. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo. Mol Cancer Ther. 2015 Dec; 14(12):2744-52. PMID: 26494858.
      View in: PubMed
    11. Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2015 May 10; 33(14):1601-8. PMID: 25847934.
      View in: PubMed
    12. Wang L, Li W, Lin M, Garcia M, Mulholland D, Lilly M, Martins-Green M. Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis. Carcinogenesis. 2014 Oct; 35(10):2321-30. PMID: 25023990.
      View in: PubMed
    13. Jia Z, Lilly MB, Koziol JA, Chen X, Xia XQ, Wang Y, Skarecky D, Sutton M, Sawyers A, Ruckle H, Carpenter PM, Wang-Rodriguez J, Jiang J, Deng M, Pan C, Zhu JG, McLaren CE, Gurley MJ, Lee C, McClelland M, Ahlering T, Kattan MW, Mercola D. Generation of "virtual" control groups for single arm prostate cancer adjuvant trials. PLoS One. 2014; 9(1):e85010. PMID: 24465467.
      View in: PubMed
    14. Mohan S, Huff E, Wish J, Lilly M, Chen SC, McClellan WM. Recovery of renal function among ESRD patients in the US medicare program. PLoS One. 2013; 8(12):e83447. PMID: 24358285.
      View in: PubMed
    15. Twardowski PW, Beumer JH, Chen CS, Kraft AS, Chatta GS, Mitsuhashi M, Ye W, Christner SM, Lilly MB. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs. 2013 Aug; 24(7):743-53. PMID: 23652277.
      View in: PubMed
    16. Khan S, Jutzy JM, Valenzuela MM, Turay D, Aspe JR, Ashok A, Mirshahidi S, Mercola D, Lilly MB, Wall NR. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One. 2012; 7(10):e46737. PMID: 23091600.
      View in: PubMed
    17. Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, Fruman DA. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 2013 Mar; 27(3):586-94. PMID: 23090679.
      View in: PubMed
    18. Robinson CA, Bottorff JL, Lilly MB, Reid C, Abel S, Lo M, Cummings GG. Stakeholder perspectives on transitions of nursing home residents to hospital emergency departments and back in two Canadian provinces. J Aging Stud. 2012 Dec; 26(4):419-27. PMID: 22939538.
      View in: PubMed
    19. Li X, Liu Z, Xu X, Blair CA, Sun Z, Xie J, Lilly MB, Zi X. Kava components down-regulate expression of AR and AR splice variants and reduce growth in patient-derived prostate cancer xenografts in mice. PLoS One. 2012; 7(2):e31213. PMID: 22347450.
      View in: PubMed
    20. Romero Rosales K, Singh G, Wu K, Chen J, Janes MR, Lilly MB, Peralta ER, Siskind LJ, Bennett MJ, Fruman DA, Edinger AL. Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins. Biochem J. 2011 Oct 15; 439(2):299-311. PMID: 21767261.
      View in: PubMed
    21. Kraft AS, Garrett-Mayer E, Wahlquist AE, Golshayan A, Chen CS, Butler W, Bearden J, Lilly M. Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther. 2011 Jul 15; 12(2):119-24. PMID: 21532336.
      View in: PubMed
    22. Shieh MP, Mitsuhashi M, Lilly M. Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML. Clin Med Insights Oncol. 2011; 5:185-99. PMID: 21792346.
      View in: PubMed
    23. Tang Y, Parmakhtiar B, Simoneau AR, Xie J, Fruehauf J, Lilly M, Zi X. Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels. Neoplasia. 2011 Feb; 13(2):108-19. PMID: 21403837.
      View in: PubMed
    24. Basu A, Banerjee H, Rojas H, Martinez SR, Roy S, Jia Z, Lilly MB, De León M, Casiano CA. Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate. 2011 May 15; 71(7):755-65. PMID: 21031435.
      View in: PubMed
    25. Cen B, Mahajan S, Zemskova M, Beharry Z, Lin YW, Cramer SD, Lilly MB, Kraft AS. Regulation of Skp2 levels by the Pim-1 protein kinase. J Biol Chem. 2010 Sep 17; 285(38):29128-37. PMID: 20663873.
      View in: PubMed
    26. Zemskova M, Lilly MB, Lin YW, Song JH, Kraft AS. p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase. Mol Cancer Res. 2010 Aug; 8(8):1126-41. PMID: 20647331.
      View in: PubMed
    27. Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar; 85(3):164-70. PMID: 20131302.
      View in: PubMed
    28. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med. 2010 Feb; 16(2):205-13. PMID: 20072130.
      View in: PubMed
    29. Nga ME, Swe NN, Chen KT, Shen L, Lilly MB, Chan SP, Salto-Tellez M, Das K. PIM-1 kinase expression in adipocytic neoplasms: diagnostic and biological implications. Int J Exp Pathol. 2010 Feb; 91(1):34-43. PMID: 19878356.
      View in: PubMed
    30. Mediavilla-Varela M, Pacheco FJ, Almaguel F, Perez J, Sahakian E, Daniels TR, Leoh LS, Padilla A, Wall NR, Lilly MB, De Leon M, Casiano CA. Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Mol Cancer. 2009 Aug 28; 8:68. PMID: 19715609.
      View in: PubMed
    31. Beharry Z, Zemskova M, Mahajan S, Zhang F, Ma J, Xia Z, Lilly M, Smith CD, Kraft AS. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther. 2009 Jun; 8(6):1473-83. PMID: 19509254.
      View in: PubMed
    32. Zhang F, Beharry ZM, Harris TE, Lilly MB, Smith CD, Mahajan S, Kraft AS. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther. 2009 May; 8(9):846-53. PMID: 19276681.
      View in: PubMed
    33. Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest. 2008 Sep; 118(9):3038-50. PMID: 18704194.
      View in: PubMed
    34. Shah N, Pang B, Yeoh KG, Thorn S, Chen CS, Lilly MB, Salto-Tellez M. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. Eur J Cancer. 2008 Oct; 44(15):2144-51. PMID: 18715779.
      View in: PubMed
    35. Zemskova M, Sahakian E, Bashkirova S, Lilly M. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem. 2008 Jul 25; 283(30):20635-44. PMID: 18426800.
      View in: PubMed
    36. Zhou J, Pan M, Xie Z, Loh SL, Bi C, Tai YC, Lilly M, Lim YP, Han JH, Glaser KB, Albert DH, Davidsen SK, Chen CS. Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia. 2008 Jan; 22(1):138-46. PMID: 17943175.
      View in: PubMed
    37. Holder S, Lilly M, Brown ML. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. Bioorg Med Chem. 2007 Oct 01; 15(19):6463-73. PMID: 17637507.
      View in: PubMed
    38. Hansen JE, Fischer LK, Chan G, Chang SS, Baldwin SW, Aragon RJ, Carter JJ, Lilly M, Nishimura RN, Weisbart RH, Reeves ME. Antibody-mediated p53 protein therapy prevents liver metastasis in vivo. Cancer Res. 2007 Feb 15; 67(4):1769-74. PMID: 17308119.
      View in: PubMed
    39. Ma J, Arnold HK, Lilly MB, Sears RC, Kraft AS. Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A. Oncogene. 2007 Aug 02; 26(35):5145-53. PMID: 17297438.
      View in: PubMed
    40. Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW, Lilly MB. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther. 2007 Jan; 6(1):163-72. PMID: 17218638.
      View in: PubMed
    41. Zemskova M, Wechter W, Bashkirova S, Chen CS, Reiter R, Lilly MB. Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase. Biochem Pharmacol. 2006 Nov 15; 72(10):1257-67. PMID: 16949054.
      View in: PubMed
    42. Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res. 2005 Aug; 3(8):443-51. PMID: 16123140.
      View in: PubMed
    43. Fodor I, Timiryasova T, Denes B, Yoshida J, Ruckle H, Lilly M. Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J Urol. 2005 Feb; 173(2):604-9. PMID: 15643273.
      View in: PubMed
    44. Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, Levis M, Small D. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood. 2005 Feb 15; 105(4):1759-67. PMID: 15498859.
      View in: PubMed
    45. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 2004 Jul 30; 571(1-3):43-9. PMID: 15280015.
      View in: PubMed
    46. Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, Lilly M. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem. 2003 Nov 14; 278(46):45358-67. PMID: 12954615.
      View in: PubMed
    47. Ionov Y, Le X, Tunquist BJ, Sweetenham J, Sachs T, Ryder J, Johnson T, Lilly MB, Kraft AS. Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects. Anticancer Res. 2003 Jan-Feb; 23(1A):167-78. PMID: 12680209.
      View in: PubMed
    48. Lombano F, Kidder MY, Lilly M, Gollin YG, Block BS. Recurrence of microangiopathic hemolytic anemia after apparent recovery from the HELLP syndrome. A case report. J Reprod Med. 2002 Oct; 47(10):875-7. PMID: 12418076.
      View in: PubMed
    49. Wu X, Daniels T, Molinaro C, Lilly MB, Casiano CA. Caspase cleavage of the nuclear autoantigen LEDGF/p75 abrogates its pro-survival function: implications for autoimmunity in atopic disorders. Cell Death Differ. 2002 Sep; 9(9):915-25. PMID: 12181742.
      View in: PubMed
    50. Frankel AE, Powell BL, Lilly MB. Diphtheria toxin conjugate therapy of cancer. Cancer Chemother Biol Response Modif. 2002; 20:301-13. PMID: 12703211.
      View in: PubMed
    51. Lilly MB, Zemskova M, Frankel AE, Salo J, Kraft AS. Distinct domains of the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit mediate activation of Jak/Stat signaling and differentiation. Blood. 2001 Mar 15; 97(6):1662-70. PMID: 11238105.
      View in: PubMed
    52. Lilly M, Sandholm J, Cooper JJ, Koskinen PJ, Kraft A. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene. 1999 Jul 08; 18(27):4022-31. PMID: 10435626.
      View in: PubMed
    53. Frankel AE, Lilly M, Kreitman R, Hogge D, Beran M, Freedman MH, Emanuel PD, McLain C, Hall P, Tagge E, Berger M, Eaves C. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Blood. 1998 Dec 01; 92(11):4279-86. PMID: 9834234.
      View in: PubMed
    54. Matsuguchi T, Lilly MB, Kraft AS. Cytoplasmic domains of the human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor beta chain (hbetac) responsible for human GM-CSF-induced myeloid cell differentiation. J Biol Chem. 1998 Jul 31; 273(31):19411-8. PMID: 9677359.
      View in: PubMed
    55. Lilly M, Kraft A. Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells. Cancer Res. 1997 Dec 01; 57(23):5348-55. PMID: 9393759.
      View in: PubMed
    56. Levin HS, Song J, Scheibel RS, Fletcher JM, Harward H, Lilly M, Goldstein F. Concept formation and problem-solving following closed head injury in children. J Int Neuropsychol Soc. 1997 Nov; 3(6):598-607. PMID: 9448373.
      View in: PubMed
    57. Matsuguchi T, Zhao Y, Lilly MB, Kraft AS. The cytoplasmic domain of granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor alpha subunit is essential for both GM-CSF-mediated growth and differentiation. J Biol Chem. 1997 Jul 11; 272(28):17450-9. PMID: 9211889.
      View in: PubMed
    58. Asiedu C, Biggs J, Lilly M, Kraft AS. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res. 1995 Sep 01; 55(17):3716-20. PMID: 7641182.
      View in: PubMed
    59. Polotskaya A, Zhao Y, Lilly MB, Kraft AS. Mapping the intracytoplasmic regions of the alpha granulocyte-macrophage colony-stimulating factor receptor necessary for cell growth regulation. J Biol Chem. 1994 May 20; 269(20):14607-13. PMID: 8182067.
      View in: PubMed
    60. Takahashi GW, Andrews DF, Lilly MB, Singer JW, Alderson MR. Effect of granulocyte-macrophage colony-stimulating factor and interleukin-3 on interleukin-8 production by human neutrophils and monocytes. Blood. 1993 Jan 15; 81(2):357-64. PMID: 7678512.
      View in: PubMed
    61. Andrews DF, Lilly MB, Tompkins CK, Singer JW. Sodium vanadate, a tyrosine phosphatase inhibitor, affects expression of hematopoietic growth factors and extracellular matrix RNAs in SV40-transformed human marrow stromal cells. Exp Hematol. 1992 May; 20(4):449-53. PMID: 1314736.
      View in: PubMed
    62. Lilly M, Le T, Holland P, Hendrickson SL. Sustained expression of the pim-1 kinase is specifically induced in myeloid cells by cytokines whose receptors are structurally related. Oncogene. 1992 Apr; 7(4):727-32. PMID: 1314369.
      View in: PubMed
    63. Lilly M, Brown C, Pettit G, Kraft A. Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia. Leukemia. 1991 Apr; 5(4):283-7. PMID: 2027297.
      View in: PubMed
    64. Lilly M, Tompkins C, Brown C, Pettit G, Kraft A. Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin. Cancer Res. 1990 Sep 01; 50(17):5520-5. PMID: 2386956.
      View in: PubMed
    65. Brezovich IA, Lilly MB, Meredith RF, Weppelmann B, Henderson RA, Brawner W, Salter MM. Hyperthermia of pet animal tumours with self-regulating ferromagnetic thermoseeds. Int J Hyperthermia. 1990 Jan-Feb; 6(1):117-30. PMID: 2299225.
      View in: PubMed
    66. Kraft AS, William F, Pettit GR, Lilly MB. Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res. 1989 Mar 01; 49(5):1287-93. PMID: 2917358.
      View in: PubMed
    67. Lilly MB, Kraft AS. Leukemia-differentiating activity expressed by the human melanoma cell line LD-1. Leuk Res. 1988; 12(3):217-25. PMID: 3163398.
      View in: PubMed
    68. Lilly MB, Devlin PE, Devlin JJ, Rado TA. Production of granulocyte colony-stimulating factor by a human melanoma cell line. Exp Hematol. 1987 Oct; 15(9):966-71. PMID: 3498641.
      View in: PubMed
    Lilly's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _